Mini ECMO Life Support System

Award Information
Agency:
Department of Health and Human Services
Branch
n/a
Amount:
$228,592.00
Award Year:
2013
Program:
STTR
Phase:
Phase I
Contract:
1R41HD075469-01
Award Id:
n/a
Agency Tracking Number:
R41HD075469
Solicitation Year:
2013
Solicitation Topic Code:
NICHD
Solicitation Number:
PA12-089
Small Business Information
3526 W Liberty Rd Ste 100 , ANN ARBOR, MI, 48103-8872
Hubzone Owned:
N
Minority Owned:
N
Woman Owned:
N
Duns:
806687406
Principal Investigator:
ROBERTBARTLETT
(734) 936-5822
robbar@umich.edu
Business Contact:
KATHRYNOSTERHOLXER
(734) 995-9089
koster@mc3corp.com
Research Institute:
UNIVERSITY OF MICHIGAN

University Of Michigan
ANN ARBOR, MI, 48109-
() -

Abstract
DESCRIPTION (provided by applicant): For twenty years prolonged extracorporeal life support (ECLS ECMO) has been standard treatment for infants with severe heart or lung failure unresponsive to other treatment. The healthy survival rate in over 30,000 cases ranges from 40% in cardiac arrest to 95% in meconium aspiration. Improved treatment has resulted in decreased need for ECMO in full term neonatal respiratory failure, but the application to respiratory failure in older infants, cardiac failure, and sepsis is increasing. The devices used fr ECMO are individual components from several manufacturers, assembled on site, and used off label. Recently three companies have combined the devices into an integrated ECMO system. These are designed for older children and adults but require substantial modification for infants. The goal of this project is to design, test, and produce a life support system specifically for infants (1 through 10 kg, 1 day to 2 years age); we call this MiniECMO. Phase l aims include integration of the MC3 BioLung and MPump devices with cartridge heat modules and an automated sweep gas controller. The system will be coated with our unique nonthrombogenic NO secreting polymer to decrease or eliminate the need for systemic anticoagulation.The prototype system will be fabricated and tested in vitro to demonstrate safety, efficacy and durability. A pilot in vivo study will be conducted to measure durability of gs exchange, properties of the MiniLung, and to evaluate thrombogenicity. Phase llwill include extended testing of MiniECMO for safety and efficacy, development of a clinical ready device, and a clinical trial for ten patients conducted under an investigational device exemption (IDE). The University of Michigan Extracorporeal Life Support Lab and Michigan Critical Care Consultants are the leaders in this field and can bring this technology to reality in four years. PUBLIC HEALTH RELEVANCE PUBLIC HEALTH RELEVANCE: The value of prolonged extracorporeal life support for infantsis well established. The success of this technology has been accomplished using a variety of devices that are designed for older children and adults, but are not well suited for infants. The goal of this research project is to design and produce a life support system specifically for infants, called MiniECMO, which will make the entire technology safer, simpler, and less expensive for current and future applications.

* information listed above is at the time of submission.

Agency Micro-sites


SBA logo

Department of Agriculture logo

Department of Commerce logo

Department of Defense logo

Department of Education logo

Department of Energy logo

Department of Health and Human Services logo

Department of Homeland Security logo

Department of Transportation logo

Enviromental Protection Agency logo

National Aeronautics and Space Administration logo

National Science Foundation logo
US Flag An Official Website of the United States Government